WES Analysis Software: What to Evaluate

Most WES pipelines can produce a VCF from a FASTQ file eventually. The real differentiators between analysis platforms show up in reproducibility, failure handling, and what happens after variant calling - annotation, classification, and reporting.

• Reproducibility: does the same input always produce the same output, with every tool version and parameter recorded?
• Failure recovery: if one sample or one stage fails mid-batch, does the whole run restart, or can it resume from the failed step?
• Parallelization: for whole-genome or large cohorts, is variant calling scattered across intervals and gathered, or run single-threaded?
• Turnaround time: what is the realistic time from upload to a completed, annotated report - and does that hold at scale?
• Output formats: are results delivered as structured, machine-readable files (VCF, TSV) in addition to a human-readable report?

• Confirm explicitly whether a platform is positioned for research use or has formal clinical/diagnostic validation - these are not interchangeable.
• Research-use platforms should say so clearly, and results should be treated as supporting evidence for expert review, not a standalone diagnosis.
• Ask what coverage depth and sample type (paired-end, exome capture kit) the pipeline was actually validated against.